CN109069513B - 用于治疗或预防肝癌的组合物 - Google Patents

用于治疗或预防肝癌的组合物 Download PDF

Info

Publication number
CN109069513B
CN109069513B CN201780023517.4A CN201780023517A CN109069513B CN 109069513 B CN109069513 B CN 109069513B CN 201780023517 A CN201780023517 A CN 201780023517A CN 109069513 B CN109069513 B CN 109069513B
Authority
CN
China
Prior art keywords
cells
hepatocellular carcinoma
pi3k
tert
hcc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780023517.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN109069513A (zh
Inventor
郑求兴
金允骏
高恩京
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shuoshi Medical Co Ltd
Original Assignee
Shuoshi Medical Co ltd
SNU R&DB Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shuoshi Medical Co ltd, SNU R&DB Foundation filed Critical Shuoshi Medical Co ltd
Publication of CN109069513A publication Critical patent/CN109069513A/zh
Application granted granted Critical
Publication of CN109069513B publication Critical patent/CN109069513B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780023517.4A 2016-02-15 2017-02-14 用于治疗或预防肝癌的组合物 Active CN109069513B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020160017187A KR101662975B1 (ko) 2016-02-15 2016-02-15 간암 치료 또는 예방용 조성물
KR10-2016-0017187 2016-02-15
PCT/KR2017/001575 WO2017142283A1 (ko) 2016-02-15 2017-02-14 간암 치료 또는 예방용 조성물

Publications (2)

Publication Number Publication Date
CN109069513A CN109069513A (zh) 2018-12-21
CN109069513B true CN109069513B (zh) 2021-12-28

Family

ID=57164552

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780023517.4A Active CN109069513B (zh) 2016-02-15 2017-02-14 用于治疗或预防肝癌的组合物

Country Status (5)

Country Link
US (1) US10463669B2 (enExample)
JP (1) JP6871638B2 (enExample)
KR (1) KR101662975B1 (enExample)
CN (1) CN109069513B (enExample)
WO (1) WO2017142283A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101662975B1 (ko) * 2016-02-15 2016-10-06 서울대학교산학협력단 간암 치료 또는 예방용 조성물
WO2019121872A1 (en) * 2017-12-20 2019-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of liver cancer
CN110665007A (zh) * 2019-09-19 2020-01-10 邦世（苏州）生物医药科技有限公司 一种治疗癌症用组合药物及其用途
KR102699871B1 (ko) 2021-04-29 2024-08-29 주식회사 서지넥스 약물전달물질로서의 간세포암 특이적 표적 엑소좀 조성물 및 이의 용도
KR20230112770A (ko) 2022-01-20 2023-07-28 가톨릭대학교 산학협력단 항섬유화 억제용 조성물
CN114796482A (zh) * 2022-05-31 2022-07-29 江苏省人民医院（南京医科大学第一附属医院） gsk3β抑制剂在制备提高抗肝细胞肝癌疗效的药物中的应用
KR20250044972A (ko) 2023-09-25 2025-04-01 주식회사 마스터메디텍 이델라리십 함유 경구투여용 고형제제 및 그 제조방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014051359A1 (ko) * 2012-09-26 2014-04-03 부경대학교 산학협력단 네퍼린을 유효성분으로 포함하는 간암 예방 또는 치료용 약제학적 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2421536B1 (en) * 2009-04-20 2015-08-26 Gilead Calistoga LLC Methods of treatment for solid tumors
US8691829B2 (en) * 2009-07-21 2014-04-08 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
WO2013082540A1 (en) * 2011-12-02 2013-06-06 Gilead Calistoga Llc Compositions and methods of treating a proliferative disease with a quinazolinone derivative
WO2014046617A1 (en) * 2012-09-19 2014-03-27 Agency For Science, Technology And Research Compositions and methods for treating cancer
CA2915250A1 (en) * 2013-06-13 2015-01-08 Biomatrica, Inc. Cell stabilization
CN104817559B (zh) * 2014-01-30 2021-05-25 苏州泽璟生物制药股份有限公司 氘代喹唑啉酮化合物以及包含该化合物的药物组合物
WO2016097314A1 (en) * 2014-12-19 2016-06-23 Sandoz Ag Amorphous and crystalline forms of idelalisib and process for forming the same
KR101662975B1 (ko) * 2016-02-15 2016-10-06 서울대학교산학협력단 간암 치료 또는 예방용 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014051359A1 (ko) * 2012-09-26 2014-04-03 부경대학교 산학협력단 네퍼린을 유효성분으로 포함하는 간암 예방 또는 치료용 약제학적 조성물

Also Published As

Publication number Publication date
WO2017142283A1 (ko) 2017-08-24
CN109069513A (zh) 2018-12-21
US20190160073A1 (en) 2019-05-30
JP2019510075A (ja) 2019-04-11
JP6871638B2 (ja) 2021-05-12
KR101662975B1 (ko) 2016-10-06
US10463669B2 (en) 2019-11-05

Similar Documents

Publication Publication Date Title
CN109069513B (zh) 用于治疗或预防肝癌的组合物
Donne et al. Replication stress triggered by nucleotide pool imbalance drives DNA damage and cGAS-STING pathway activation in NAFLD
RU2666921C2 (ru) СПОСОБ ПРЕДСКАЗАНИЯ ТЕРАПЕВТИЧЕСКОЙ ЭФФЕКТИВНОСТИ ИНГИБИТОРА PI3K/AKT/mTOR НА ОСНОВАНИИ ЭКСПРЕССИИ PHLDA1 ИЛИ PIK3C2B
Chen et al. Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth
CN111154869B (zh) 肝癌诊断的生物标志物及其试剂盒
CN107106580B (zh) 治疗癌症干细胞的组合物
Yuan et al. TIPE3 is a regulator of cell apoptosis in glioblastoma
US20210353721A1 (en) Methods and compositions relating to inhibiting cardiovascular calcification via annexin a1
Wang et al. Studying the mechanism of sperm DNA damage caused by folate deficiency
WO2018025923A1 (ja) 抗ｈｔｌｖ－１剤、ｈｔｌｖ－１関連脊髄症（ｈａｍ／ｔｓｐ）治療薬
Liu et al. Neutrophil extracellular traps promote gastric cancer cell metastasis via the NAT10-mediated N4-acetylcytidine modification of SMYD2
US20180057888A1 (en) Kub5/hera as a determinant of sensitivity to dna damage
Yan et al. Extracellular polysaccharide from Rhizopus nigricans inhibits hepatocellular carcinoma via miR-494-3p/TRIM36 axis and cyclin E ubiquitination
JP2023500950A (ja) マントル細胞リンパ腫（ｍｃｌ）対象を特定するための鉄スコアおよびインビトロ方法ならびに治療的使用および方法
RU2665952C2 (ru) Синтетическая летальность и лечение рака
US20170342503A1 (en) Xrn2 as a determinant of sensitivity to dna damage
Zheng et al. Long non-coding RNA ZNF667-AS1 retards the development of esophageal squamous cell carcinoma via modulation of microRNA-1290-mediated PRUNE2
TWI595879B (zh) Prediction of therapeutic effect in patients with colorectal cancer with TK1 protein hyperactivity
WO2011129427A9 (ja) 癌の診断剤および治療剤
JP2023016207A (ja) Ｆｇｆｒ阻害薬に対する感受性の判定方法
CN111701025A (zh) 用于治疗肾细胞癌的药物及其应用
JPWO2014042148A1 (ja) がんマーカーおよびその用途
US8697681B2 (en) Method for prediction of therapeutic effect of chemotherapy employing expression level of dihydropyrimidine dehydrogenase gene as measure
Xue et al. EP300 Modulates MCM8 Transcription and Augments the Malignant Phenotype of Hepatitis B Virus–Positive Hepatocellular Carcinoma Cells
WO2025225410A1 (ja) 肝線維化、肝硬変、及び肝がんの予防又は治療剤、並びに類洞内圧バイオマーカー

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200604

Address after: Seoul, South Kerean

Applicant after: Shuoshi Medical Co., Ltd

Address before: Seoul, South Kerean

Applicant before: SNU R&DB FOUNDATION

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant